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1.1. Need for developing case definitions and guidelines for data
Collection, Analysis, and presentation for respiratory distress in the
neonate as an adverse event following maternal immunization
Definition of respiratory distress in the neonate
Every year, an estimated 2.9 million babies die in the neonatal
period (the first 28 days of life), accounting for more than half of
the under-five child deaths in most regions of the world, and 44%
globally [1]. The majority (75%) of these deaths occur in the first
week of life, with the highest risk of mortality concentrated in the
first day of life [2]. Ninety-nine percent of neonatal deaths occur in
low- and middle-income countries; south-central Asian countries
experience the highest absolute numbers of neonatal deaths, while
countries in sub-Saharan Africa generally have the highest rates of
neonatal mortality [2].
Respiratory distress is one of the most common problems neo-
nates encounter within the first few days of life [3]. According to
the American Academy of Pediatrics, approximately 10% of neo-
nates need some assistance to begin breathing at birth, with upto 1% requiring extensive resuscitation [4]. Other reports confirm
that respiratory distress is common in neonates and occurs in
approximately 7% of babies during the neonatal period [3,5]. Respi-
ratory disorders are the leading cause of early neonatal mortality
(0–7 days of age) [6], as well as the leading cause of morbidity in
newborns [7], and are the most frequent cause of admission to
the special care nursery for both term and preterm infants [8]. In
fact, neonates with respiratory distress are 2–4 times more likely
to die than neonates without respiratory distress [9].
Respiratory distress describes a symptom complex representing
a heterogeneous group of illnesses [3]. As such, respiratory distress
is often defined as a clinical picture based on observed signs and
symptoms irrespective of etiology [7,10]. Clinical symptoms most
commonly cited as indicators of respiratory distress include
tachypnea [3,7–8,10–17], nasal flaring [3,7–8,10–15,17], grunting
[3,7–8,10–17], retractions [3,7–8,10–17] (subcostal, intercostal,
supracostal, jugular), and cyanosis [3,7–8,10–11,13,17]. Other
symptoms include apnea [3,8], bradypnea [8], irregular (seesaw)
breathing [8], inspiratory stridor [3,16], wheeze [16] and hypoxia
[8,14].
Tachypnea in the newborn is defined as a respiratory rate of
more than 60 breaths per minute [12,15], bradypnea is a respira-
tory rate of less than 30 breaths per minute, while apnea is a ces-
sation of breath for at least 20 s [18]. Apnea may also be defined
as cessation of breath for less than 20 s in the presence of bradycar-
dia or cyanosis [18]. Nasal flaring is a compensatory symptom that
is caused by contraction of alae nasi muscles, increases upper air-
Table 1
Etiologies of respiratory distress in the neonate [8,12,13,15,17].
Pulmonary
Congenital Pulmonary hypoplasia, congenital diaphragmatic hernia,
chylothorax, pulmonary sequestration, congenital cystic
adenomatous malformation of the lung, arteriovenous
malformation, congenital lobar emphysema, congenital
alveolar proteinosis, alveolar capillary dysplasia, congenital
pulmonary lymphangiectasis, surfactant protein deficiency
Acquired Transient tachypnea of the newborn, respiratory distress
syndrome, meconium aspiration syndrome, pneumonia,
pneumothorax, pneumomediastinum, atelectasis,
pulmonary hemorrhage, bronchopulmonary dysplasia,
persistent pulmonary hypertension of the newborn,
diaphragmatic paralysis, drug reaction, anaphylactic
reaction, hypersensitivity syndrome, inhalation exposure
Extrapulmonary
Airway Nasal obstruction, choanal atresia, nasal stenosis,
micrognathia, Pierre Robin anomaly, cleft palate,
macroglossia, glossoptosis, laryngeal stenosis or atresia,
tracheal atresia, laryngeal cyst or web, vocal cord paralysis,
subglottic stenosis, hemangioma, papilloma,
laryngomalacia, tracheobronchomalacia, tracheobronchial
stenosis, tracheoesophageal fistula, vascular rings, cystic
hygroma and external compression from other neck masses
Cardiovascular Transposition of the great arteries, tetralogy of fallot, large
septal defects, patent ductus arteriosus, coarctation of the
aorta, congestive heart failure, cardiomyopathy,
pneumopericardium
Hematologic Polycythemia, anemia, severe hemolytic disease,
hypovolemia, hereditary hemoglobinopathies, hereditary
methemoglobinemia
Infectious Sepsis, bacteremia, meningitis
Metabolic Hypoglycemia, hypocalcemia, hypermagnesemia, hypo- or
hypernatremia, inborn errors of metabolism
Neuromuscular Hypoxic-ischemic encephalopathy, intracranial
hemorrhage, hydrocephalus, seizure, narcotic withdrawal,
muscle and spinal cord disorders
Thoracic Skeletal dysplasias
Miscellaneous Asphyxia, acidosis, hypothermia, hyperthermia, hydrops
fetalis
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[8,12,15]. Stridor is a high-pitched, musical, monophonic inspira-
tory breath sound that indicates obstruction at the larynx, glottis,
or subglottic area [15].Wheezing is a high-pitched, whistling, expi-
ratory, polyphonic sound that indicates tracheobronchial obstruc-
tion [15]. Grunting is an expiratory sound caused by sudden
closure of the glottis during expiration in an attempt to increase
airway pressure and lung volume, and to prevent alveolar atelecta-
sis [8,12,15]. Retractions occur when lung compliance is poor or air-
way resistance is high, result from negative intrapleural pressure
generated by contraction of the diaphragm and accessory chest
wall muscles, and are clinically evident by the use of accessory
muscles in the neck, rib cage, sternum, or abdomen [8,15]. Finally,
cyanosis is assessed by examining the oral mucosa for blue or gray
discoloration and suggests inadequate gas exchange, while hypox-
emia is signified by an oxygen saturation of less than 90% after
15 min of life [8].
Pathophysiology of respiratory distress in the neonate
Most causes of respiratory distress result from an inability or
delayed ability of a neonate’s lungs to adapt to their new environ-
ment [14]. In utero, the lungs are fluid filled, receive less than 10–
15% of the total cardiac output, and oxygenation occurs through
the placenta [8,19–21]. For the neonate to transition, effective
gas exchange must be established [8,22], alveolar spaces must be
cleared of fluid and ventilated [20,21], and pulmonary blood flow
must increase to match ventilation and perfusion [14,23]. A small
proportion of alveolar fluid is cleared by Starling forces and vaginal
squeeze [14,23], however the overall process is complex, and
entails rapid removal of fluid by ion transport across the airway
and pulmonary epithelium [8,20,23]. Peak expression of these ion
channels in the alveolar epithelium is achieved at term gestation,
leaving preterm infants with a reduced ability to clear lung fluid
after birth [14]. If ventilation or perfusion is inadequate, the neo-
nate develops respiratory distress [14,23].
In utero, high pulmonary vascular resistance directs blood from
the right side of the heart through the ductus arteriosus into the
aorta [8]. When the umbilical vessels are clamped at birth the
low-resistance placental circuit is removed, systemic blood pres-
sure is increased, and the pulmonary vasculature relaxes [8,20].
Expansion of the lungs and increase in PaO2 results in increased
pulmonary blood flow and constriction of the ductus arteriosus
[8,21]. Cardiopulmonary transition is completed after approxi-
mately 6 h [8]. The neonate’s respiratory pattern may initially be
irregular, but soon becomes rhythmic at a rate of 40–60 breaths
per minute [8]. A neonate’s first breaths tend to be deeper and
longer than subsequent breaths [19], they are characterized by a
short deep inspiration followed by a prolonged expiratory phase
[24]. This breathing pattern helps the neonate develop and main-
tain functional residual capacity [24].
Causes of respiratory distress in the neonate
Respiratory distress may be the clinical presentation of numer-
ous conditions that affect the neonate (see Table 1). Specific causes
of respiratory distress may be difficult to ascertain based on clini-
cal presentation alone. The most common causes of respiratory
distress in the newborn are pulmonary in origin and include tran-
sient tachypnea of the newborn, respiratory distress syndrome,
meconium aspiration syndrome, pneumonia, sepsis, pneumotho-
rax, persistent pulmonary hypertension of the newborn, and
delayed transition [13]. Extrapulmonary etiologies, such as con-
genital heart defects, airway malformations, inborn errors of meta-
bolism, neurologic, and hematologic causes are less common [13].
Transient Tachypnea of the Neonate (TTN) is the most common
etiology of respiratory distress in the neonatal period [8,13]. TTN
occurs in near-term, term and late preterm infants, and affects
3.6–5.7 per 1000 term infants, and up to 10 per 1000 preterm
infants [8,17]. TTN is a result of delayed resorption and clearanceof alveolar fluid from the lungs [5,13]. Following delivery, the
release of prostaglandins distends lymphatic vessels which remove
lung fluid as pulmonary circulation increases following the first
fetal breath [13]. Cesarean section prior to the onset of labor
bypasses this process, and is therefore a risk factor for TTN
[8,13,17]. Other risk factors include surfactant deficiency [13],
maternal asthma, diabetes, prolonged labor, and fetal distress
requiring maternal anesthesia or analgesia [8,17,25]. TTN presents
within the first two hours after birth and can persist for up to 72 h
[13]. Clinical presentation includes rapid, shallow breathing with
occasional grunting or nasal flaring [17], and rarely respiratory fail-
ure [8]. Breath sounds may either be clear, or reveal rales on aus-
cultation [13]. TTN is generally a self-limited disorder [5],
however, the higher the initial respiratory rate, the longer TTN is
likely to last [13].
Respiratory Distress Syndrome (RDS) is seen soon after birth, and
worsens during the first few hours of life [8,17]. RDS occurs
because of surfactant deficiency or dysfunction resulting in
increased alveolar surface tension and alveolar collapse at the
end of expiration [8,17]. The disease progresses rapidly [13], with
increased work of breathing, intrapulmonary shunting, ventilation
perfusion mismatch, and hypoxia with eventual respiratory failure
[8,17]. The risk of RDS is inversely proportional to gestational age;
RDS occurs in approximately 5% of near-term infants, 30% of
infants less than 30 weeks gestational age, and 60% of premature
infants less than 28 weeks gestational age [8,17]. Additional factors
associated with development of RDS are male sex in Caucasians,
infants born to mothers with diabetes, perinatal asphyxia,
hypothermia, multiple gestations, cesarean delivery without labor,
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include tachypnea, grunting, retractions and cyanosis [8,13].
Meconium Aspiration Syndrome (MAS) occurs in term or post-
term infants born through meconium-stained amniotic fluid [17],
and is seen within a few hours after birth [8]. Although meco-
nium-stained amniotic fluid is present in 10–15% of deliveries,
most infants born to mothers with meconium-stained amniotic
fluid are asymptomatic, and the incidence of MAS is only 1%
[8,13]. Meconium excretion is representative of fetal maturity,
therefore MAS is most commonly seen in term and post-term neo-
nates [13]. Meconium is passed in utero when the fetus is dis-
tressed and relaxes the anal sphincter [17]. The resultant hypoxia
and subsequent gasping lead to aspiration of meconium before
birth [5,8]. Meconium consists of desquamated cells, skin, lanugo
hair, vernix, bile salts, pancreatic enzymes, lipids, mucopolysac-
charides, and water [8,17]. Chemical pneumonitis occurs when bile
salts and other components of meconium deactivate pulmonary
surfactant resulting in atelectasis [8]. Meconium also activates
the complement cascade, causing inflammation and constriction
pulmonary veins [8,17]. Risk factors include preeclampsia, mater-
nal diabetes, chorioamnionitis, and illicit substance abuse [8].
MAS presents with tachypnea, grunting, retractions and cyanosis
[13]. Affected neonates may have a barrel-shaped chest, rales and
rhonchi heard on auscultation, and meconium staining of the nails
and umbilical cord [8,13,17].
Pneumonia is a significant cause of respiratory distress in the
neonate and may be classified as early-onset (less than or equal
to 7 days of age) or late-onset (greater than 7 days of age) [8].
Early-onset pneumonia most commonly occurs within the first
three days of life, and is the result of placental transmission of bac-
teria or aspiration of infected amniotic fluid, while late-onset
pneumonia occurs after hospital discharge and community expo-
sure, resulting in various potential etiologies including viral and
bacterial pathogens [13]. The clinical signs in neonatal pneumonia
mimic other conditions like TTN, RDS or MAS, making it difficult to
distinguish them [5,8,17].
Assessment of respiratory distress in the neonate
Initial assessment of an infant with respiratory distress should
focus on the physical examination and rapid identification of life-Table 2
Comparison of validated neonatal scoring system measurements.
Neonatal scoring systems
Variable Respiratory specific
ACorN Silverman
Time dependent
assessment
NA NA
Respiratory rate
(breaths/min,
apnea)
Yes NA
Nasal flaring NA NA
Grunting Yes Yes
Intercostal retractions Yes Yes
Cyanosis NA NA
Mean blood pressure NA NA
Oxygen measurement
or requirement
Yes NA
Temperature NA NA
Heart rate NA NA
Blood sugar NA NA
Urine output NA NA
Neurologic NA NA
Breath sounds on
auscultation
Yes NA
Other Prematurity Paradoxic chest and abdominal
movements (see-saw respirations)
Xiphoid retraction
Chin descending with respirations
a If indicated by past history.threatening conditions [8,17]. Assessment for respiratory distress
may differ depending on clinical setting but should include at least
some of the following parameters: (1) measurement of respiratory
rate (normal 40–60); (2) observation for increased work of breath-
ing: inspiratory sternal, intercostal and subcostal recession/in-
drawing, tracheal tug; (3) assessment for airway noises such as
expiratory grunting or inspiratory stridor; (4) assessment for nasal
flaring or head bobbing; (5) assessment of color for cyanosis, ide-
ally pulse oximetry measurement should be obtained if any con-
cern about color/cyanosis. Apnea should prompt urgent medical
assessment. Respiratory distress may be accompanied by
increased, decreased, or normal respirations depending on the
level of respiratory fatigue the infant is experiencing. Therefore,
respiratory rate alone may not be indicative of the degree of dis-
tress. Utilizing a validated scoring system can improve the predic-
tive value of the degree of respiratory distress and aid the
practitioner in accessing additional support services in a timely
fashion.
If providers are able to identify signs of respiratory distress
prior to the onset of refractory disease, this may facilitate early
intervention, and reduced morbidity and mortality [11]. Early
warning tools may aid in the early identification of neonates at
risk for clinical deterioration. These tools may also provide a stan-
dardized observation chart for monitoring clinical progress, and
provide visual prompts to aid identification of abnormal parame-
ters. Early identification of ill neonates and early intervention
may facilitate early transfer to higher level care if necessary and
available [26].
Several scoring systems focused specifically on assessment of
respiratory distress in the neonate are available. The World Health
Organization provides the most simplified scoring system, which
classifies breathing difficulty based on respiratory rate, grunting
and chest in-drawing [27] (see Appendix A). Other respiratory
specific scoring systems include the ACoRN (Acute Care of at-Risk
Newborns) Respiratory Score [11], the Silverman Scoring System
[15,28,29], and the Downes Respiratory Distress Score (Downes
RDS) [15,30] (see Appendix A and Table 2). These respiratory speci-
fic scoring systems are based on clinical criteria, and therefore can
be implemented in most settings.General neonatal illness
Downes SNS SNAP-II NTS
NA NA Yes, over 12 h Yes, over 12 h
Yes Yes NA Yes
NA NA NA Yes, as components of
‘respiratory distress’Yes Yes NA
Yes NA NA
Yes NA NA
NA Yes Yes NA
NA Yes, SpO2 (room
air)
Yes, PO2/FiO2 and pH
(blood gas)
NA
NA Yes Yes Yes
NA Yes NA Yes
NA Yes NA Yesa
NA NA Yes NA
NA NA Yes, seizure Yes, level of conscious
Yes NA NA NA
NA Capillary filling
time (sec)
NA NA
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general neonatal illness scoring systems. These include the Sick
Neonate Score (SNS) [31], the Score for Neonatal Acute Physiology
II (SNAP-II) [32], and the Neonatal Trigger Score (NTS) [33] (see
Appendix B and Table 2). Although by definition these scores are
more representative of overall neonatal illness, each does take res-
piratory symptoms into account, and therefore may also help
determine the presence of respiratory distress in the neonate.
SNS is a clinical score that was developed to assess neonatal illness
in resource limited settings [31]. SNAP-II and NTS require 12 h of
data collection, and SNAP-II requires assessment of urine output
and a blood gas, which may make it more difficult to implement
these scoring systems in some settings [11,32,33].
Respiratory Distress in the Neonate following maternal
immunization
Influenza vaccine is recommended for pregnant women in
many countries at any time during pregnancy to prevent infection
in both the pregnant woman and her neonate [34]. The safety of
influenza vaccine during pregnancy has been studied with no evi-
dence of safety concerns when administered in any trimester [34–
36]. Although three systematic reviews have supported the evi-
dence for no safety signal, there are limitations on the amount of
evidence available, especially for more specific pregnancy out-
comes such as congenital malformations, in women receiving
influenza vaccine in the first trimester [35]. Respiratory symptoms
in the neonate following maternal immunization are rarely
reported [37]. In a large retrospective database review over 5 influ-
enza seasons, Muñoz et al. reported on ‘‘respiratory problems” in
the neonate within 2 days of birth. No infants had respiratory prob-
lems if their mother had received influenza vaccine during preg-
nancy, compared to 8 infants with respiratory problems whose
mother had not received influenza vaccine, however this difference
was not statistically significant (p = 0.2) [38].
The evaluation of low APGAR scores (<7) as an adverse event
following maternal influenza immunization, and which includes
an assessment of respiratory effort, has been reported in six studies
[39–44]. These studies mostly relate to pandemic influenza vaccine
(influenza A H1N1 09 vaccine) with one reporting on influenza A
Hsw1N1 vaccine [39]. Only the study by Håberg et al. had a point
estimate that favored the unvaccinated cohort, although this was
close to the null value and did not reach statistical significance
(HR = 1.08 (95% CI, 0.91–1.28) [41]. The remainder of the cohort
studies had a point estimate that favored the vaccinated cohort.
A prospective cohort study reported an unadjusted OR = 0.88 (CI
95% 0.35–2.20) and a retrospective cohort study reported a
RR = 0.97 (95% CI 0.82, 1.14) for APGAR < 7 [39,40]. A cross-sec-
tional study indicated a protective effect against 5 min APGAR
score <7, unadjusted OR = 0.7 (95% CI 0.47–1.05) [44]. None of
the studies demonstrated any statistical or clinical association with
decreased APGAR scores.
Pertussis-containing vaccines used in pregnant women often
contain tetanus toxoid, diphtheria toxoid, acellular pertussis, and
inactivated poliomyelitis antigens (Tdap or Tdap-IPV). In pregnant
women, administration of a lower antigen pertussis-containing
vaccine is recommended during the third trimester of pregnancy
(or earlier in some countries), to ensure maximal and timely pro-
tection for neonates [45,46]. Large cohort studies examining the
safety of Tdap/Tdap-IPV vaccine administered in pregnancy have
not identified any safety concerns [47–52]. Morgan et al. provide
the only published data on respiratory outcomes in neonates in
pregnant women who have received Tdap vaccine. In this retro-
spective cohort study comparing women who did and did not
receive Tdap vaccine in pregnancy, no difference was observed in
infants with a 5-min APGAR score <4 [48]. No difference was
observed between these groups in neonatal complications, includ-ing requirement for ventilation in the first 24 h. A subgroup analy-
sis of multiparous women who received at least 2 doses of Tdap
vaccine in the past 5 years compared to one dose of Tdap demon-
strated comparable neonatal outcomes, including ventilation
requirements [48].
Existing case definitions for respiratory distress in the
neonate
Respiratory distress in the newborn is a common clinical syn-
drome with many possible etiologies. Several definitions of respi-
ratory distress are currently available from a variety of
organizations and in the literature. These are summarized in
Table 3. If not cited, no specific definition was identified from cer-
tain organizations (e.g. American Academy of Pediatrics, CIOMS,
MedDRA).
Need for a harmonized definition of respiratory distress in
the neonate
There is no uniformly accepted case definition of Respiratory
Distress in the Neonate in the context of assessing adverse events
following maternal immunization. There is variability in existing
definitions, which decreases their specificity. Data comparability
across trials or surveillance systems would facilitate data interpre-
tation, improve harmonization across clinical and population stud-
ies, and promote the scientific understanding of Respiratory
Distress in the Neonate.
1.2. Methods for the development of the case definition and guidelines
for data collection, analysis, and presentation for respiratory distress
in the neonate as an adverse event following maternal immunization
Following the process described in the overview papers [53,54]
as well as on the Brighton Collaboration Website http://www.
brightoncollaboration.org/internet/en/index/process.html, the
Brighton Collaboration Respiratory Distress in the Neonate Working
Group was formed in 2016 and included members of various clin-
ical, academic, public health, and industry backgrounds. The com-
position of the working and reference group as well as results of
the web-based survey completed by the reference group with sub-
sequent discussions in the working group can be viewed at: http://
www.brightoncollaboration.org/internet/en/index/working_groups.
html.
To guide the decision-making for the case definition and guide-
lines, literature searches were performed using PubMed, Medline,
Embase, Clinical Key and the Cochrane Libraries. One literature
search focused on general descriptions of respiratory distress in
the neonate, was conducted using PubMed, searched English lan-
guage articles only, and used the search terms ‘‘respiratory dis-
tress” and ‘‘neonate”. The search resulted in 4000 articles from
2006 to present, all titles and abstracts were reviewed. Fifty-four
articles with potentially relevant material were reviewed in full
to identify case definitions, background rates, etiologies and patho-
physiology of respiratory distress in the neonate.
Of the 54 articles reviewed on respiratory distress and the neo-
nate, 33 were relevant, and a total of 16 definitions of respiratory
distress in the neonate were identified (Table 3). These case defini-
tions were noted to contain similar elements, but there was varia-
tion in terminology used, number and type of symptoms
considered, and application of the definition. An inventory of the
16 relevant case definitions of Respiratory Distress in the Neonate
was made available to working group members.
An additional search was conducted to identify literature about
maternal immunization in relation to respiratory distress in the
neonate. This search utilized the terms ‘‘maternal immunization,
vaccine, vaccines, vaccination, immunization, pregnancy, neonatal,
neonate, newborn, infant, respiratory distress, respiratory insuffi-
ciency, apnoea, apnea, apneic attack, apnoeic attack, respiratory
Table 3
Existing case definitions of respiratory distress in the neonate.
Source Definition
World Health Organization Respiratory rate more than 60 or less than 30 breaths per minute, grunting on expiration, chest indrawing, or
central cyanosis [blue tongue and lips], apnoea (spontaneous cessation of breathing for more than 20 s)
NCI/NICHD Increased work of breathing with tachypnea and retractions
2016 ICD-10 CM diagnosis code A condition of the newborn marked by dyspnea with cyanosis, heralded by such prodromal signs as dilatation
of the alae nasi, expiratory grunt, and retraction of the suprasternal notch or costal margins, most frequently
occurring in premature infants, children of diabetic mothers, and infants delivered by cesarean section, and
sometimes with no apparent cause
Kumar M, et al. Arch Dis Child Fetal Neonatal Ed
2014;99:F116.
One or more of the following: need for supplemental oxygen > or = 2 h and/or positive pressure ventilation
(CPAP or endotracheal intubation) following admission to neonatal intensive care unit
Swiss Society of Neonatology Definition in Ersch et al.
Acta Paediatrica 2007;96:1577
Presence of at least two of the following criteria: tachypnea (>60 breaths per minute), central cyanosis in
room air, expiratory grunting, subcostal, intercostal or jugular retractions and nasal flaring. Entirely based on
clinical observation irrespective of etiology
Ma X, et al. Chin Med J 2010;123(20):2777 Clinical signs of effort breathing, such as tachypnea, grunting, intercostal retraction, nasal flaring and cyanosis
Qian L, et al. Chin Med J 2010;123(20):2770 At least two of the following criteria: tachypnea, central cyanosis in room air, expiratory grunting, sub-costal,
intercostals or jugular retractions and nasal flaring. Entirely based on clinical observation irrespective of
etiology
Pramanik AK, et al. Pediatr Clin N Am 2015;62:454–55 Tachypnea (rate >60 breaths per minute), cyanosis, expiratory grunting with chest retractions, and nasal
flaring. Decrease in oxygen saturation, apnea or both may be present. Irregular (seesaw) or slow respiratory
rates of less than 30 breaths per minute if associated with gasping may be an ominous sign
Hermansen CL, et al. Am Fam Physician 2015;92
(11):994
Tachypnea is most common presentation. Other signs may include nasal flaring, grunting, intercostal or
subcostal retractions, and cyanosis
Parkash A, et al. JPMA 2015;65:771 Presence of one or more of the following clinical features: respiratory rate >60 breaths/minute, chest wall
retraction, grunting, nasal flaring and cyanosis
Mahoney AD, et al. Clin Perinatol 2013;40:666 Sustained distress for more than 2 h after birth accompanied by grunting, flaring, tachypnea, retractions, or
supplemental oxygen requirement
Reuter S, et al. Ped Rev 2014;35(10):418 Recognized as one or more signs of increased work of breathing, such as tachypnea, nasal flaring, chest
retractions, or grunting
Hermansen CL, et al. Am Fam Physician 2007;76:987 The clinical presentation includes apnea, cyanosis, grunting, inspiratory stridor, nasal flaring, poor feeding,
and tachypnea (more than 60 breaths per minute). There may also be retractions in the intercostal, subcostal,
or supracostal spaces
Warren JB, et al. Pediatr Rev 2010;31(12):487–95 Most commonly presents as one or all of the following physical signs: tachypnea, grunting, nasal flaring,
retractions and cyanosis
Edwards MO, et al. Pediatric Respiratory Reviews
2013;14:30
Recognized as any signs of breathing difficulties in the neonate. Tachypnea (RR > 60/min) & tachycardia
(HR > 160/min, cyanosis, nasal flaring, grunting, apnoea/dyspnoea, chest wall recessions (suprasternal,
intercostal & subcostal)
Mathai SS, et al. MJAFI 2007;63:269 Diagnosed when one or more of the following is present: tachypnoea or respiratory rate of more than 60/min,
retractions or increased chest in drawings on respirations (subcostal, intercostal, sternal, suprasternal) and
noisy respiration in the form of a grunt, stridor, or wheeze. The distress may or may not be associated with
cyanosis and desaturation on pulse oximetry
6510 L.R. Sweet et al. / Vaccine 35 (2017) 6506–6517arrest, respiratory failure, respiratory acidosis, respiratory compli-
cations, difficulty breathing, increased work of breathing, labored
respiration, pneumonia, pulmonary, respiratory tract, pulmonary
edema, pulmonary oedema, alveolitis, lung infiltration, interstitial
lung disease”. The search was limited to publications from 2005
to present, and concentrated on reviews or large clinical studies.
The search resulted in the identification of 56 references, 9 of
which were book chapters. All English language article abstracts
were screened for possible reports of Respiratory Distress in the
Neonate following maternal immunization. Forty-seven articles
with potentially relevant material were reviewed in more detail,
in order to identify studies using case definitions or, in their
absence, providing clinical descriptions of the case material. This
review resulted in a detailed summary of 47 articles, including
information on the study type, the vaccine, the diagnostic criteria
or case definition put forth, the time interval since time of immu-
nization, and any other symptoms.
Of the 47 articles reviewed on immunization and respiratory
distress, 17 focused on maternal immunization, while 30 focused
on infant immunization. Most of the papers on maternal immu-
nization did not mention Respiratory Distress in the Neonate as
an adverse event that was considered in relation to maternal
immunization. When respiratory distress was mentioned in a
few of these articles it was not clearly defined. The 30 articles
related to infant immunization were not relevant, as they focused
on infants immunized outside of the neonatal age range, and were
not related to maternal immunization.1.3. Rationale for selected decisions about the case definition of
respiratory distress in the neonate as an adverse event following
maternal immunization
The term Respiratory Distress in the Neonate refers to a constel-
lation of clinical findings that support the presence of breathing
difficulty in the neonate (0 to 28 days of life), independent from
etiology or severity, and independent from the infant’s gestational
age or circumstances at the time of delivery. Respiratory distress is
distinct from the clinical findings observed during normal transi-
tion from intra- to extra- uterine life in all newborns. Different ter-
minology exists in the literature in relation to respiratory distress
in the neonate, from a very broad characterization as ‘‘increased
work of breathing” or ‘‘dyspnea”, to various measurable findings
(e.g. respiratory rate), to observing for the presence of clinical find-
ings consistent with difficulty breathing (e.g. expiratory grunting,
chest retractions) or with the consequences of poor oxygenation
(e.g. central cyanosis), to, in some cases, laboratory findings (e.g.
arterial blood gas analysis).
Different terminologies in the literature that refer to the clinical
syndrome of Respiratory Distress in the Neonate were identified,
including: respiratory distress, difficulty breathing, labored breath-
ing, shortness of breath, increased work of breathing, labored res-
pirations, respiratory insufficiency, respiratory failure, respiratory
arrest, respiratory acidosis, respiratory complications, respiratory
disease, respiratory illness, and respiratory disorder. The term
Respiratory Distress Syndrome is utilized specifically to designate
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ratory Distress in the Neonate selected for this case definition.
Numerous related term(s) of Respiratory Distress in the Neo-
nate exist in the literature. Some have the observed clinical find-
ings associated with respiratory distress in neonates (e.g. apnea,
apneic attack, bradypnea, tachypnea, dyspnea, retractions, reces-
sions, use of accessory muscles, cyanosis, grunting, stridor, nasal
flaring, wheezing), while others reflect the possible etiologies of
respiratory distress (e.g. Respiratory Distress Syndrome, hyaline
membrane disease, surfactant deficiency lung disease, meconium
aspiration syndrome, transient tachypnea of the newborn, persis-
tent pulmonary hypertension of newborn, hypoxia, pneumonia,
pulmonary edema, alveolitis, lung infiltration, interstitial lung
disease).
Disparity in the use of respiratory distress during the neonatal
period may result in inconsistent classifications for adverse event
reporting. It is important to highlight that when choosing to report
on an adverse event associated with vaccination, the most precise
definition or description of the event should be cataloged. There-
fore, although respiratory distress may often present as a symptom
of a disease, the more precise disease etiology should be the term
chosen for the adverse event (e.g. meconium aspiration would be
more precise than respiratory distress, although both would be
present for the single situation).
Focus of brighton collaboration case definition
The focus of the Working Group was to identify all the neces-
sary components to define Respiratory Distress in the Neonate,
and to produce a harmonized definition to properly identify cases
of respiratory distress in the neonate in the context of vaccination
of mothers during pregnancy. Within the definition context, how-
ever, the three diagnostic levels must not be misunderstood as
reflecting different grades of clinical severity. They instead reflect
diagnostic certainty (see below). Furthermore, the definition may
be applied to settings other than studies of vaccines in pregnancy.
The Brighton Collaboration case definition of respiratory dis-
tress in the neonate is based on clinical observation only, utilizing
auscultation with stethoscope when available. However, support-
ing evidence from certain devices may be utilized in certain clinical
settings, such as pulse oximetry or a cardiac and respiratory mon-
itor. The definition based on clinical criteria is applicable in differ-
ent settings, independent from resources. However, collection of
additional information based on laboratory, imaging, or pathology
results is encouraged to ascertain the cause of the syndrome man-
ifesting as respiratory distress in the newborn. A summary of
potential etiologies is described in Table 1.
Formulating a case definition that reflects diagnostic cer-
tainty: weighing specificity versus sensitivity
It needs to be re-emphasized that the grading of definition
levels is entirely about diagnostic certainty, not clinical severity
of an event. Thus, a clinically very severe event may appropriately
be classified as Level Two or Three rather than Level One if it could
not reasonably be confirmed to fit within the case definition of Res-
piratory Distress in the Neonate. Detailed information about the
severity of the event should additionally always be recorded, as
specified by the data collection guidelines.
The number of symptoms and/or signs that will be docu-
mented for each case may vary considerably. The case definition
has been formulated such that the Level 1 definition is highly
specific for the condition. As maximum specificity normally
implies a loss of sensitivity, two additional diagnostic levels have
been included in the definition, offering a stepwise increase of
sensitivity from Level One down to Level Three, while retaining
an acceptable level of specificity at all levels. In this way it is
hoped that all possible cases of Respiratory Distress in the Neo-
nate can be captured.The meaning of ‘‘Sudden Onset” and ‘‘Rapid progression” in
the context of respiratory distress in the neonate
The term ‘‘sudden onset” refers to an event that occurred unex-
pectedly and without warning leading to a marked change in a
subject’s previously stable condition.
The term ‘‘rapid progression” is a conventional clinical term.
Respiratory distress may be classified as occurring unexpectedly
and of being of ‘‘sudden onset”, and clinical progression can be
assesses as ‘‘rapid” by the provider. An exact time-frame of what
rapid progression is should not be offered since progression may
be associated with wide range of potential etiologies. Documenta-
tion of these characteristics however, should be helpful during the
evaluation of respiratory distress in the neonate, in order to corre-
late with potential etiologies and interventions.
Rationale for individual criteria or decision made related to
the case definition
Pathology findings
Pathology is not necessary for the ascertainment of respiratory
distress in the neonate, given that the diagnosis of respiratory dis-
tress is based on clinical observation. However, pathology findings
are helpful for the identification of etiologic causes of respiratory
distress in the newborn.
Radiology findings
Radiology findings are not necessary for the ascertainment of
respiratory distress in the neonate, given that the diagnosis of res-
piratory distress is based on clinical observation. However, radiol-
ogy findings are helpful for the identification of etiologic causes of
respiratory distress in the newborn, specifically for the identifica-
tion of pulmonary vs. extrapulmonary causes of respiratory
distress.
Laboratory findings
Laboratory findings are not necessary for the ascertainment of
respiratory distress in the neonate, given that the diagnosis of res-
piratory distress is based on clinical observation. However, labora-
tory findings are helpful for the identification of etiologic causes of
respiratory distress in the newborn. For example, the result of arte-
rial or venous blood gas analysis can confirm the presence of
hypoxemia, and the presence of leukocytosis or a positive blood
culture can identify an infectious etiology for respiratory distress.
Influence of treatment on fulfillment of case definition
The Working Group decided against using ‘‘treatment” or
‘‘treatment response” towards fulfillment of the Respiratory Dis-
tress in the Neonate case definition.
A treatment response or its failure is not in itself diagnostic, and
may depend on variables like clinical status, time to treatment, and
other clinical parameters.
An important consideration is that practically all newborns will
require some form of reanimation after delivery (e.g. stimulation,
suctioning of secretions, blow by oxygen, etc.), and that infants
may present with clinical findings at birth that could be considered
part of the clinical manifestations of Respiratory Distress (e.g.
tachypnea, bradypnea, apnea, nasal flaring, retractions and cyano-
sis). However, these routine clinical findings and interventions
should NOT be considered for the fulfillment of the case definition
of respiratory distress in the neonate if they occur and then dissi-
pate with standard delivery/post-delivery care in the first 10 min
of life. Interventions that are beyond routine neonatal reanimation
at birth needed to support an infant who meets the case definition
of respiratory distress, should be documented.
Timing post maternal immunization
Specific time frames for onset of Respiratory Distress in the
Neonate following maternal immunization are not included as a
consideration when ascertaining the case definition. By our defini-
tion Respiratory Distress in the Neonate occurs after delivery to
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between maternal immunization and delivery is variable depend-
ing on the study design and other events of pregnancy.
We postulate that a definition designed to be a suitable tool for
testing causal relationships requires ascertainment of the outcome
(e.g. Respiratory Distress in the Neonate) independent from the
exposure (e.g. maternal immunizations). Therefore, to avoid selec-
tion bias, a restrictive time interval from maternal immunization
to onset of Respiratory Distress in the Neonate should not be an
integral part of such a definition. Instead, where feasible, details
of this interval should be assessed and reported as described in
the data collection guidelines.
Further, Respiratory Distress in the Neonate may occur outside
the controlled setting of a clinical trial or hospital. In some settings
it may be impossible to obtain a clear timeline of the event, partic-
ularly in less developed or rural settings. In order to avoid selecting
against such cases, the Brighton Collaboration case definition
avoids setting arbitrary time frames.
Differentiation from other (similar/associated) disorders
Respiratory Distress in the Neonate is distinct from normal
signs and symptoms of transition to extrauterine life occurring
immediately after delivery. These are transient and not associated
with any pathology, typically resolving after stimulation and not
requiring specific treatment. It is also distinct from Respiratory
Distress Syndrome (RDS), a term used to describe a very specific
condition, also known as surfactant deficiency or hyaline mem-
brane disease of the newborn. See more detailed description in
Section 1.1.
1.4. Guidelines for data collection, analysis and presentation
As mentioned in the overview paper, the case definition is
accompanied by guidelines which are structured according to the
steps of conducting a clinical trial or conducting vaccine safety
monitoring, i.e. data collection, analysis and presentation. Neither
case definition nor guidelines are intended to guide or establish
criteria for management of ill infants, children, or adults. Both were
developed to improve data comparability.
1.5. Periodic review
Similar to all Brighton Collaboration case definitions and guide-
lines, review of the definition with its guidelines is planned on a
regular basis (i.e. every three to five years) or more often if needed.
2. Case definition of respiratory distress in the neonate
For All Levels of Diagnostic Certainty
Respiratory Distress in the Neonate is a clinical syndrome
occurring in Newborns 0 to 28 days of life, characterized by the
presence of:
Abnormal respiratory rate
Measurement of number of breaths per minute consistent with:
Tachypnea = respiratory rate of 60 or more breaths per minute
OR
Bradypnea = respiratory rate of less than 30 breaths per minute
OR
Apnea = cessation of respiratory effort (no breaths) for at least
20 s
AND
Clinical symptoms consistent with labored breathing
Clinical observation of:Nasal flaring (dilatation of alae nasi)
OR
Noisy respirations in the form of expiratory grunting, stridor, or
wheeze
OR
Retractions or increased chest indrawings on respiration (sub-
costal, intercostal, sternal, suprasternal notch)
OR
Central cyanosis (whole body, including lips and tongue) on
room air
OR
Low Apgar Score (<7 points) at 10 min, with respiration score <2
The ascertainment of respiratory distress in the neonate is inde-
pendent from the newborn’s gestational age at the time of delivery
and the circumstances of delivery, and distinct from the clinical
manifestations of the immediate normal transition from intrauter-
ine to extrauterine life. Clinical findings should therefore be persis-
tent beyond the first 10 min of life (when Apgar scores are
collected), or occur at any time after this transition period and
before day of life 28. Clinical findings consistent with respiratory
distress should be assessed prior to any intervention or assistance
needed in response to the findings. Ascertainment of the diagnosis
is not dependent on the need for, or results of, medical interven-
tions or the type of intervention initiated (e.g. need for supplemen-
tal oxygen, positive pressure support, or mechanical ventilation).
Provision of respiratory support (e.g. airway placement, oxygen
supplementation) in itself is not always indicative of Respiratory
Distress in the Neonate. Furthermore, the absence of an abnormal
respiratory rate does not rule out the diagnosis of respiratory dis-
tress in infants who have had an abnormal respiratory rate, tran-
siently appear normal, and continue to deteriorate. The case
definition identifies cases of respiratory distress in the neonate,
independently from the cause or the severity of the clinical find-
ings of respiratory distress.
Additional supporting evidence of respiratory distress (but not
required for case ascertainment) may include: Hypoxemia docu-
mented by pulse oximetry or arterial or venous blood gas analysis,
presence of tachycardia or bradycardia, decreased muscular tone,
flaccid/limp muscles, body or extremities, hypo-responsiveness,
and obtundation.
Diagnostic levels of certainty
Level 1
Newborn 0 to 28 days of life
AND
Abnormal respiratory rate
Measurement of number of breaths per minute consistent with:
Tachypnea = respiratory rate of 60 or more breaths per minute
OR
Bradypnea = respiratory rate of less than 30 breaths per minute
OR
Apnea = cessation of respiratory effort (no breaths) for at least
20 s
AND
Clinical symptoms consistent with labored breathing
Nasal flaring (dilatation of alae nasi)
OR
Noisy respirations in the form of expiratory grunting, stridor, or
wheeze
OR
Retractions or increased chest indrawings on respiration (sub-
costal, intercostal, sternal, suprasternal notch)
OR
3 If the reporting center is different from the vaccinating center, appropriate and
timely communication of the adverse event should occur.
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room air
OR
Low Apgar Score (< 7 points) at 10 min, with respiration
score < 2
AND
Examination and documentation by qualified, trained, health
care provider appropriate for the clinical setting.
Level 2
Newborn 0 to 28 days of life
AND
Abnormal respiratory rate
Not measured, but reported as ‘‘rapid breathing”, ‘‘slow breath-
ing”, having periods of ‘‘no breathing”, or ‘‘abnormal breathing”
AND
Clinical symptoms consistent with labored breathing
Nasal flaring (dilatation of alae nasi)
OR
Noisy respirations in the form of expiratory grunting, stridor, or
wheeze
OR
Retractions or increased chest indrawings on respiration (sub-
costal, intercostal, sternal, suprasternal notch) or seesaw
respirations
OR
Central cyanosis (whole body, including lips and tongue) on
room air
OR
Low Apgar Score (<7 points) at 10 min, with respiration score <2
AND
No medical record documentation, but reporting through either
a non-medical observer (e.g. mother, father, community
worker) or via standard census mechanisms (e.g. Demographic
and Health Surveillance System)
OR
Collection of information from medical record review or billing
codes.
Level 3
No need for a level 3 per working group.
Level 4
Not enough information to ascertain case of respiratory
distress.
Level 5
Not a case of respiratory distress in the neonate.
3. Guidelines for data collection, analysis and presentation of
respiratory distress in the neonate
It was the consensus of the GAIA-Brighton Collaboration Respi-
ratory Distress in the Neonate Working Group to recommend the fol-
lowing guidelines to enable meaningful and standardized
collection, analysis, and presentation of information about Respira-
tory Distress in the Neonate in studies of vaccines given during
pregnancy. However, implementation of all guidelines might not
be possible in all settings. The availability of information may vary
depending upon resources, geographical region, and whether the
source of information is a prospective clinical trial, a post-market-ing surveillance or epidemiological study, or an individual report of
Respiratory Distress in the Neonate. Also, these guidelines have
been developed by this working group for guidance only, and are
not to be considered a mandatory requirement for data collection,
analysis, or presentation.
3.1. Data collection
These guidelines represent a desirable standard for the collec-
tion of data on availability following maternal immunization to
allow for comparability of data, and are recommended as an addi-
tion to data collected for the specific study question and setting.
The guidelines are not intended to guide the primary reporting of
Respiratory Distress in the Neonate to a surveillance system or
studymonitor. Investigators developing a data collection tool based
on these data collection guidelines also need to refer to the criteria
in the case definition, which are not repeated in these guidelines.
Guidelines number 1–43 below have been developed to address
data elements for the collection of adverse event information as
specified in general drug safety guidelines by the International
Conference on Harmonization of Technical Requirements for Regis-
tration of Pharmaceuticals for Human Use [55], and the form for
reporting of drug adverse events by the Council for International
Organizations of Medical Sciences [56]. These data elements
include an identifiable reporter and patient, one or more prior
immunizations, and a detailed description of the adverse event,
in this case, of Respiratory Distress in the Neonate following
maternal immunization. The additional guidelines have been
developed as guidance for the collection of additional information
to allow for a more comprehensive understanding of Respiratory
Distress in the Neonate following maternal immunization.
3.1.1. Source of information/reporter
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(1) Date of report.
(2) Name and contact information of person reporting3 and/or
diagnosing Respiratory Distress in the Neonate as specified
by country-specific data protection law.
(3) Name and contact information of the investigator responsi-
ble for the subject, as applicable.
(4) Relation to the patient (e.g. immunizer [clinician, nurse],
family member [indicate relationship], other).
3.1.2. Vaccinee/control
3.1.2.1. Demographics. For all cases and/or all study participants
(mothers and infants), as appropriate, the following information
should be recorded:
(5) Case/study participant identifiers (e.g. first name initial fol-
lowed by last name initial) or code (or in accordance with
country-specific data protection laws).
(6) Date of birth, age, and sex.
(7) For infants: Gestational age and birth weight.3.1.2.2. Clinical and immunization history. For all cases and/or all
study participants (mothers and infants), as appropriate, the fol-
lowing information should be recorded:
(8) Past medical history, including hospitalizations, underlying
diseases/disorders, pre-immunization signs and symptoms
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history of allergy to vaccines, vaccine components or medi-
cations; food allergy; allergic rhinitis; eczema; asthma.
(9) Any medication history (other than treatment for the event
described) prior to, during, and after immunization includ-
ing prescription and non-prescription medication as well
as medication or treatment with long half-life or long term
effect. (e.g. immunoglobulins, blood transfusion and
immunosuppressants).
(10) Immunization history (i.e. previous immunizations and any
adverse event following immunization (AEFI)), in particular
occurrence of Respiratory Distress in the Neonate after a
previous maternal immunization. Of note, ascertainment of
maternal immunization history might be challenging in dif-
ferent settings, and collection of data from different sources
might be necessary to optimize data gathering.
3.1.3. Details of the immunization
For all cases and/or all study participants, as appropriate, the
following information should be recorded:
(11) Date and time of maternal immunization(s).
(12) Description of vaccine(s) (name of vaccine, manufacturer, lot
number, dose (e.g. 0.25 mL, 0.5 mL, etc.), name and lot num-
ber of any diluent used in the vaccine, and number of dose if
part of a series of immunizations against the same disease).
(13) The anatomical sites (including left or right side) of all
immunizations (e.g. vaccine A in proximal left lateral thigh,
vaccine B in left deltoid).
(14) Route and method of administration (e.g. intramuscular,
intradermal, subcutaneous, and needle-free (including type
and size), other injection devices).
(15) Needle length and gauge.
3.1.4. The adverse event
(16) For all cases at any level of diagnostic certainty and for
reported events with insufficient evidence, the criteria ful-
filled to meet the case definition should be recorded.
(17) Specifically document: Clinical description of signs and
symptoms of Respiratory Distress in the Neonate, and if
there was medical confirmation of the event (i.e. patient
seen by physician).
(18) Date/time of onset4, first observation5 and diagnosis6, end of
episode7 and final outcome.8
(19) Concurrent signs, symptoms, and diseases.
(20) Measurement/testing4 The
first sig
may on
5 The
Respira
6 The
met the
7 The
definitio
8 E.g.
peutic i
9 An AEFI is defined as serious by international standards if it meets one or more of Values and units of routinely measured parameters (e.g.
respirations per minute, heart beats per minute, temper-
ature) – in particular those indicating the severity of the
event;
 Method of measurement (e.g. respiratory monitor, pulse
oximeter, duration of measurement, cardiac etc.);
 Results of laboratory and radiographic examinations, sur-
gical and/or pathological findings anddiagnoses if present.date and/or time of onset is defined as the time post immunization, when the
n or symptom indicative of Respiratory Distress in the Neonate occurred. This
ly be possible to determine in retrospect.
date and/or time of first observation of the first sign or symptom indicative of
tory Distress in the Neonate can be used if date/time of onset is not known.
date of diagnosis of an episode is the day post immunization when the event
case definition at any level.
end of an episode is defined as the time the event no longer meets the case
n at the lowest level of the definition.
recovery to pre-immunization health status, spontaneous resolution, thera-
ntervention, persistence of the event, sequelae, death.(21) Treatment given for Respiratory Distress in the Neonate
(22) Outcome8 at last observation.
(23) Objective clinical evidence supporting classification of the
event as ‘‘serious”.9
(24) Exposures (e.g. food, environmental) considered potentially
relevant to the reported event.
3.1.5. Miscellaneous/general
(25) The duration of surveillance for Respiratory Distress in the
Neonate is predefined based on the duration of the neonatal
period of 28 days.
(26) The duration of follow-up reported during the surveillance
period should be predefined likewise. It should aim to con-
tinue to resolution of the event.
(27) Methods of data collection should be consistent within and
between study groups, if applicable.
(28) Follow-up of cases should attempt to verify and complete
the information collected as outlined in data collection
guidelines 1–24.
(29) Investigators of patients with Respiratory Distress in the
Neonate should provide guidance to reporters to optimize
the quality and completeness of information provided.
(30) Reports of Respiratory Distress in the Neonate should be col-
lected throughout the study period regardless of the time
elapsed between maternal immunization and the adverse
event. If this is not feasible due to the study design, the study
periods during which safety data are being collected should
be clearly defined.
3.2. Data analysis
The following guidelines represent a desirable standard for
analysis of data on Respiratory Distress in the Neonate to allow
for comparability of data, and are recommended as an addition
to data analyzed for the specific study question and setting.
(31) Reported events should be classified in one of the following
five categories including the three levels of diagnostic cer-
tainty. Events that meet the case definition should be classi-
fied according to the levels of diagnostic certainty as
specified in the case definition. Events that do not meet
the case definition should be classified in the additional cat-
egories for analysis.
Event classification in 5 categories10
Event meets case definition
(1) Level 1: Criteria as specified in the Respiratory Distress in the
Neonate case definition
(2) Level 2: Criteria as specified in the Respiratory Distress in the
Neonate case definitionthe following criteria: 1) it results in death, 2) is life-threatening, 3) it requires
inpatient hospitalization or results in prolongation of existing hospitalization, 4)
results in persistent or significant disability/incapacity, 5) is a congenital anomaly/
birth defect, 6) is a medically important event or reaction.
10 To determine the appropriate category, the user should first establish, whether a
reported event meets the criteria for the lowest applicable level of diagnostic
certainty. If the lowest applicable level of diagnostic certainty of the definition is met,
and there is evidence that the criteria of the next higher level of diagnostic certainty
are met, the event should be classified in the next category. This approach should be
continued until the highest level of diagnostic certainty for a given event could be
determined. If the lowest level of the case definition is not met, it should be ruled out
that any of the higher levels of diagnostic certainty are met and the event should be
classified in additional categories four or five.
L.R. Sweet et al. / Vaccine 35 (2017) 6506–6517 6515(3) Level 3: Criteria as specified in the Respiratory Distress in the
Neonate case definition (if applicable)
Event does not meet case definition
Additional categories for analysis
(4) Reported Respiratory Distress in the Neonate with insuffi-
cient evidence to meet the case definition11
(5) Not a case of Respiratory Distress in the Neonate12
(32) The interval between maternal immunization and reported
Respiratory Distress in the Neonate could be defined as the
date/time of maternal immunization to the date/time of
onset3 of the first symptoms and/or signs consistent with
the definition. In this case, it is probably important to distin-
guish cases of Respiratory Distress occurring in the immedi-
ate post-delivery period (within 10 min), those occurring in
the first week after delivery (early neonatal period or 0–
6 days of life), and those occurring at or after the 7th day
and up to 28 days of life (late neonatal period). Determining
the interval from maternal vaccination to the event is prob-
ably more relevant for those cases occurring immediately at
the time of delivery. However, in all cases, the interval
between maternal vaccination(s) and the date of birth
should be recorded. For a large number of cases, data could
be analyzed in the following increments:
Subjects with Respiratory Distress in the Neonate by Interval
to PresentationInterval⁄ Number/
percentage
Cases occuring after delivery and in the first
28 days of life
Immediately (within 10 min) after delivery
At 0–6 days of life
At 7–28 days of life
Total(33) The duration of possible Respiratory Distress in the Neonate
could be analyzed as the interval between the date/time of
onset3 of the first symptoms and/or signs consistent with
the definition and the end of episode7 and/or final outcome8.
Whatever start and ending are used, they should be used
consistently within and across study groups.
(34) If more than one measurement of a particular criterion is
taken and recorded, the value corresponding to the greatest
magnitude of the adverse experience could be used as the
basis for analysis. Analysis may also include other character-
istics like qualitative patterns of criteria defining the event.
(35) The distribution of data (as numerator and denominator
data) could be analyzed in predefined increments (e.g. mea-
sured values, times), where applicable. Increments specified
above should be used. When only a small number of cases is
presented, the respective values or time course can be pre-
sented individually.11 If the evidence available for an event is insufficient because information is
missing, such an event should be categorized as ‘‘Reported Respiratory Distress in the
Neonate with insufficient evidence to meet the case definition”.
12 An event does not meet the case definition if investigation reveals a negative
finding of a necessary criterion (necessary condition) for diagnosis. Such an event
should be rejected and classified as ‘‘Not a case of Respiratory Distress in the
Neonate”.(36) Data on Respiratory Distress in the Neonate obtained from
infants of subjects receiving a vaccine should be compared
with those obtained from one or more appropriately
selected and documented control groups to assess back-
ground rates in non-exposed populations, and should be
analyzed by study arm and dose where possible, e.g. in
prospective clinical trials.
3.3. Data presentation
These guidelines represent a desirable standard for the presen-
tation and publication of data on Respiratory Distress in the Neo-
nate following maternal immunization to allow for comparability
of data, and are recommended as an addition to data presented
for the specific study question and setting. Additionally, it is rec-
ommended to refer to existing general guidelines for the presenta-
tion and publication of randomized controlled trials, systematic
reviews, and meta-analyses of observational studies in epidemiol-
ogy (e.g. statements of Consolidated Standards of Reporting Trials
(CONSORT), of Improving the quality of reports of meta-analyses
of randomized controlled trials (QUORUM), and of meta-analysis
Of Observational Studies in Epidemiology (MOOSE), respectively)
[57–59].
(37) All reported events of Respiratory Distress in the Neonate
should be presented according to the categories listed in
guideline 32.
(38) Data on possible Respiratory Distress in the Neonate events
should be presented in accordance with data collection
guidelines 1–24 and data analysis guidelines 31–36.
(39) Terms to describe Respiratory Distress in the Neonate such
as ‘‘mild”, ‘‘moderate”, ‘‘severe” or ‘‘significant” are highly
subjective, prone to wide interpretation, and should be
avoided, unless clearly defined.
(40) Data should be presented with numerator and denominator
(n/N) (and not only in percentages), if available.
Although immunization safety surveillance systems denomina-
tor data are usually not readily available, attempts should be made
to identify approximate denominators. The source of the denomi-
nator data should be reported and calculations of estimates be
described (e.g. manufacturer data like total doses distributed,
reporting through Ministry of Health, coverage/population based
data, etc.).
(41) The incidence of cases in the study population should be
presented and clearly identified as such in the text.
(42) If the distribution of data is skewed, median and range are
usually the more appropriate statistical descriptors than a
mean. However, the mean and standard deviation should
also be provided.
(43) Any publication of data on Respiratory Distress in the Neo-
nate should include a detailed description of the methods
used for data collection and analysis as possible. It is essen-
tial to specify:
 The study design;
 The method, frequency and duration of monitoring for
Respiratory Distress in the Neonate;
 The trial profile, indicating participant flow during a
study including drop-outs and withdrawals to indicate
the size and nature of the respective groups under
investigation;
 The type of surveillance (e.g. passive or active
surveillance);
 The characteristics of the surveillance system (e.g. popu-
lation served, mode of report solicitation);
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 Comparison group(s), if used for analysis;
 The instrument of data collection (e.g. standardized ques-
tionnaire, diary card, report form);
 Whether the day of immunization was considered ‘‘day
one” or ‘‘day zero” in the analysis;
 Whether the date of onset4 and/or the date of first
observation5 and/or the date of diagnosis6 was used for
analysis; and
 Use of this case definition for Respiratory Distress in the
Neonate, in the abstract or methods section of a
publication.13Disclaimer
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